In which clinical settings do you use the Cerianna (fluoroestradiol F18) PET scan for breast cancer?  

The established clinical utility of FES PET in guidelines is to detect the presence of ER+ metastatic disease in instances where a biopsy is inconclusive, difficult, or not possible. Some other scenarios where FES PET may be useful include: Decalcified bone lesion biopsies where ER IHC may be false...

The FDA approved FES-PET (CERIANNA) in 2020 as an adjunct to biopsy of metastatic ER-positive breast cancer. The approval language was careful in view of the limited prospective data and potential limitations of the imaging modality.  Some of the limitations include false negative results, ina...